Bafna Pharmaceuticals Quarterly Results for Trading Insights
In Sept 2019, Bafna Pharmaceuticals (BAFNAPH) reported revenue ₹12 Cr and net profit ₹-1 Cr — revenue +33.3% YoY. Also explore BAFNAPH share price charts to track price trends across different timeframes.
BAFNAPH Quarterly Results — Revenue, Profit & EPS Highlights
Bafna Pharmaceuticals latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Browse BAFNAPH complete financial statements for revenue, profit, balance sheet and cash flow data.
- Revenue of ₹12 Cr in Sept 2019 (+71.4% vs Jun 2019, +33.3% vs Sept 2018)
- Net Profit of ₹-1 Cr in Sept 2019 (+50.0% vs Jun 2019, +0.0% vs Sept 2018)
- Operating Margin of -3.0% in Sept 2019 (+39.0pp vs Jun 2019)
- Earnings Per Share of ₹-0.25 in Sept 2019 (+72.2% vs Jun 2019)
Bafna Pharmaceuticals Quarterly Results — Revenue, EBITDA, Net Profit & EPS
BAFNAPH quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2019 | Jun 2019 | Sept 2018 | Jun 2018 | QoQ | YoY |
|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 12 | 7 | 9 | 12 | 71.4% | 33.3% |
| Net Profit (₹ Cr) | -1 | -2 | -1 | -4 | - | - |
| EBITDA (₹ Cr) | 0 | -3 | 0 | -2 | - | - |
| EPS (₹) | -0.25 | -0.90 | -0.80 | 0.00 | - | - |
| Operating Margin (%) | -3.0% | -42.0% | 2.0% | -15.0% | - | - |
BAFNAPH Share Price Trend — 1-Year Movement Across Quarterly Results
Bafna Pharmaceuticals 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Bafna Pharmaceuticals share price today.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
BAFNAPH vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Bafna Pharmaceuticals latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹457,721.13 Cr | 1904.8 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 168.6 |
|
Divis Laboratories
Mar 2026 |
₹174,081.02 Cr | 6757.0 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 238.7 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹161,380.94 Cr | 4768.3 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 414.3 |
|
Cipla
Mar 2026 |
₹117,800.00 Cr | 1458.2 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 212.3 |
|
Zydus Life Science
Mar 2026 |
₹115,505.60 Cr | 1140.6 | 7,569 | 1,341 | +23.1% | +18.8% | 17.7% | 90.2 |
All amounts in ₹ Crores